

PERSONAL INFORMATION

Paolo Solla

📍 29, Via Enrico Fermi, Maracalagonis (CA), 09069, ITALY

☎ +39 3272555636

📠 +39 3272555636

✉ psolla@uniss.it

ACTUAL JOB

Chief Neurological Clinic AOU Sassari, University of Sassari
Associate Professor of Neurology at the Medical School of the University of Sassari

WORK EXPERIENCE

2021-ongoing Director of the Neurological Clinic of the University, AOU Sassari. Neurological Clinic is a structure dedicated to the Diagnosis and Treatment of neurological diseases in adults, and to the development of Research in the field of common and rare disorders of the Central and Peripheral Nervous System.

2021-ongoing Associate Professor of Neurology, Department of Medicine, Surgery and Pharmacy, University of Sassari

2016-2021 Neurologist consultant at Neurological Clinic, AOU Cagliari

2012-2016 Assistant Professor type A, Department Medical Sciences and Public Health, University of Cagliari

2009-2012 Neurologist consultant at Neurological Clinic, AOU Cagliari

2008-2009 Neurologist consultant at Oncological Neurosurgery, ASL Cagliari

2007-2008 Research Fellow on the project "Epidemiological and genetic study on the risk of sclerosis multiple in a cohort of Sardinian" (MED/26), Department of Cardiovascular and Neurological Sciences, University of Cagliari.

EDUCATION AND TRAINING

Classical high school diploma in 1990, obtained at the Liceo Classico Siotto in Cagliari.

- Degree in Medicine and Surgery from the University of Cagliari in 2001 with score of 110/110 and honors

- Specialization in Neurology at the University of Cagliari in 2006 with score of 50/50 cum laude

- Postgraduate Diploma in Electromyography from the University of Barcelona in 2007

- PhD in Cardiovascular Sciences at the Department of Sciences Cardiovascular and Neurological Studies of the University of Cagliari, from 15/02/2010, with final thesis on 14/05/2013, entitled "Non-motor symptoms and cardiovascular dysautonomia in Sardinian patients with Parkinson's disease with and without mutations of the LRRK2 gene "

- Achievement of National Scientific Qualification for the Competition Sector 06 / D6 - Band II with effect from 28/03/2017 to 28/03/2026

GRANTS PARTICIPATIONS

International Grants

GRANT_ -STSM NUMBER: ECOST -BM1101-300315-059207(Pisa Syndrome in patients affected by Parkinson's disease and other atypical parkinsonisms. 2015-03 to 2015-04 | Grant, Dystonia Europe (Brussels, Belgium, BE)

GRANT_ NUMBER: ECOST-STSM-BM1101-020514-043037, 2014-05 to 2014-05| Grant, Dystonia Europe (Brussels, Belgium, BE)

National and Regional Grants

Scientific director of the project "Study of cardiovascular reflexes in Sardinian patients suffering from Parkinson's disease and their correlation with motor and non-motor disorders", at the Department of Public Health, Clinical and Molecular Medicine, at the University of Cagliari, from 2013 to 2015, with funding from the Fondazione di Sardegna.

Scientific director of the project "Sardinian dance and Parkinson's disease: study of the efficacy of a non-pharmacological therapeutic approach on motor rehabilitation and non-motor symptoms of disease", at Department of Public Health, Clinical and Molecular Medicine, at the University of Cagliari, from 2014 to 2016, with funding from the Fondazione di Sardegna

SCIENTIFIC SOCIETY MEMBERSHIPS

2007-at present: Member of LIMPE- DISMOV

2007-at present: Member of Italian Society of Neurology (SIN).

2011-at present: Member of The International Parkinson and Movement Disorder Society (MDS)

2025 at present: Member of The Italian Association of Myology

2024 at present: Member of SIAMOC (Società italiana di analisi del Movimento in clinica)

2024 at present: Member of Scientific Technical Committee "Fondazione LIMPE"

ACADEMIC POSITION

From 05/02/2007 to 10/08/2008: Research fellow on the project "Epidemiological and genetic study on the risk of sclerosis multiple in a cohort of Sardinian patients at the SCIENCE Department CARDIOVASCULAR AND NEUROLOGICAL, University of CAGLIARI

From 31/10/2012 to 30/10/2016: Researcher at the University of the Studies of CAGLIARI, Dept. of Medical Sciences and Public Health for the three-year period

From 01/02/2021 to present: Associate Professor of Neurology at the Medical School of the University of Sassari

From 2021 to present: PhD Academic Board Member in Life Sciences and Biotechnologies of the University of Sassari

RESEARCH GROUP/TRIAL PARTICIPATION

Principal investigator (AOU Sassari Center) in the multicenter interventional pharmacological study CITIPARK (Role of Citicoline in Supportive Therapy in Parkinson's Disease), 2019–2022.

Principal investigator (AOU Sassari Center) in the multicenter observational study "Studio osservazionale multicentrico italiano, real-life per la conferma dell'efficacia, tollerabilità e sicurezza di farmaci innovativi (anticorpi monoclonali) nella profilassi dell'emicrania episodica e cronica -PROTOCOLLO iNEED (NEW migrainE drugs Database)", cod. prot. i-NEED, 2023-ongoing

Principal investigator (AOU Sassari Center) in the multicenter observational study "Dissecting the genetic architecture of CIPD", cod. prot. GeArCIPD (NEU2-OSS-2022-001), 2023- ongoing

Principal investigator (AOU Sassari Center) in the multicenter observational study " Impatto della mutazione GBA1 su efficacia e sicurezza del trattamento con infusione digiunale continua di levodopa-carbidopa in pazienti affetti da Malattia di Parkinson. Uno studio multicentrico, retrospettivo, caso-controllo. Studio Duo-GBA , 2023- ongoing

Principal investigator in the Project "Studio longitudinale prospettico della funzione olfattiva ed altri sintomi motori e non motori in pazienti affetti da malattia di parkinson", Prot. OSMIPARK (Prot. CE Sardegna PG/2023/7846), 2023-ongoing

Participation as CoPI in the project PNRR 2023: PNRR-MCNT1-2023-12376993 "Human endogenous retrovirus K and propagation of TDP-43 proteinopathy", AOU Sassari- 2023-ongoing"

Principal investigator of the Research Unit of University of Sassari, Project PRIN 2022: 2022XT88XL_006: Investigating vascular predictors of poor visual outcome in the multidisciplinary management of immune-mediated optic neuritis (ON-COLOUR) - 2023-ongoing

Participation as co-investigator in the multicenter study group "StayHome Working Group" [with work published in J Neurol. 2025 Jan 7;272(1):96. doi: 10.1007/s00415-024-12749-8. J.

Participation as co-investigator in the multicenter observational study "Global response during infusion of a gel with Levodopa/carbidopa" (Greenfield), Protocol: 13-895; years 2013–2016.

Participation as co-investigator in the multicenter observational study "Predictive factors of quality of life and caregiver stress in Parkinson's disease" (PREDICT), Protocol: IT-13-08; year 2015.

Participation as co-investigator in the international multicenter non-interventional study aimed at evaluating the effectiveness of NEUPRO (rotigotine transdermal patch) and combination therapy with levodopa in patients with Parkinson's disease (NEUPART) (Protocol PD0013), years 2015–2016.

Participation as co-investigator in the national study group "ITALIAN LEVODOPA CARBIDOPA INTESTINAL GEL WORKING GROUP" [with work published in Parkinsonism and Related Disorders, 2017 May;38:90–92. DOI: 10.1016/j.parkreldis.2017.02.020].

Participation in the multicenter observational study "TANDEM" [with work published in Journal of Neural Transmission (Vienna), 2020 Mar 24. DOI: 10.1007/s00702-020-02175-1].

Role of Co-PI in RAS Project titled: "Validation of salivary alpha-synuclein as a non-invasive biomarker for diagnosis and progression in Parkinson's disease" – year 2017, ongoing

Participation in the research group of the Italian multicenter observational study DEEP [Early DEtection of wEaring off in Parkinson's disease] (year 2010) [with work published in Parkinsonism and Related Disorders – DOI: 10.1016/j.parkreldis.2013.10.027].

Participation in the research group on adapted preventive motor activity in patients with Parkinson's disease and other neurological disorders, directed by Prof. Giuseppe Mercuro, with at least two full-text publications available on PUBMED (in the journal *Neurorehabilitation*, with the following DOIs: 10.3233/NRE-151257 and 10.3233/NRE-141162).

Participation as co-investigator in the role of Examining Neurologist in the multicenter observational study "Impulse control disorders and the association of neuropsychiatric symptoms, cognition, and quality of life in Parkinson's disease" (ICARUS), 2011–2015

PUBLICATIONS (LAST 5 YEARS)

- 1: Zara P, Chessa P, Deiana GA, Morette AM, Puci M, Sotgiu G, Damato V, Solla P, Sechi E. Risk of False Acetylcholine Receptor Autoantibody Positivity by Radioimmunoprecipitation Assay in Clinical Practice. *Neurology*. 2025 May 13;104(9):e213498. doi: 10.1212/WNL.0000000000213498.
- 2: Velucci V, Gigante AF, Illiceto G, Pellicciari R, Vitucci B, Idrissi S, Mascia MM, Muroi A, Ercoli T, Solla P, Defazio G. The natural history of body-first versus brain-first Parkinson's disease subtypes. *J Neurol*. 2025 Apr 9;272(5):325. doi: 10.1007/s00415-025-13050-y. PMID: 40204988; PMCID: PMC11982158.
- 3: Marongiu A, Galleri P, Mura A, Solla P, Madeddu G, Spanu A, Nuvoli S. ¹⁸F-FDG Brain PET/CT Metabolic Imaging in Patients with Suspected Autoimmune Encephalitis (AE) in the Early Stage: Can the Procedure Play a Complementary Diagnostic Role? *Brain Sci*. 2025 Jan 24;15(2):113. doi: 10.3390/brainsci15020113. PMID: 40002446; PMCID: PMC11852412.
- 4: Falso S, Zara P, Marini S, Puci M, Sabatelli E, Sotgiu G, Marini M, Spagni G, Evoli A, Solla P, Iorio R, Sechi E. Seasonal variation in myasthenia gravis incidence. *J Neuroimmunol*. 2025 Feb 15;399:578524. doi: 10.1016/j.jneuroim.2025.578524. Epub 2025 Jan 9. PMID: 39799766.
- 5: Filippi M, Gallo P, Gasperini C, Marfia GA, Avolio C, Bergamaschi R, Capobianco M, Dotta M, Grimaldi L, Lus G, Patti F, Pucci E, Quatralo R, Solla P, Bandiera P, Angioletti C, Gallotini MC, Parretti S, Pinto L, Pavone F, Sanzone S; StayHome Project Working Group. Implementing proximity care for people with multiple sclerosis in Italy: the bottom-up approach of the StayHome project. *J Neurol*. 2025 Jan 7;272(1):96. doi: 10.1007/s00415-024-12749-8. PMID: 39775071; PMCID: PMC11706871.
- 6: Lodde V, Zarbo IR, Farina G, Masia A, Solla P, Campesi I, Delogu G, Muroi MR, Tsitsipatis D, Gorospe M, Floris M, Idda ML. Identification of *hsa_circ_0018905* as a New Potential Biomarker for Multiple Sclerosis. *Cells*. 2024 Oct 9;13(19):1668. doi: 10.3390/cells13191668. PMID: 39404430; PMCID: PMC11475351.
- 7: Ashraf H, Dikarlo P, Masia A, Zarbo IR, Solla P, Ijaz UZ, Sechi LA. *Mycobacterium avium* subspecies paratuberculosis (MAP) infection, and its impact on gut microbiome of individuals with multiple sclerosis. *Sci Rep*. 2024 Oct 14;14(1):24027. doi: 10.1038/s41598-024-74975-4. PMID: 39402079; PMCID: PMC11479286.
- 8: Masala C, Porcu M, Orofino G, Defazio G, Pinna I, Solla P, Ercoli T, Suri JS, Spinato G, Saba L. Neuroimaging evaluations of olfactory, gustatory, and neurological deficits in patients with long-term sequelae of COVID-19. *Brain Imaging Behav*. 2024 Dec;18(6):1480-1490. doi: 10.1007/s11682-024-00936-0. Epub 2024 Sep 28. PMID: 39340624; PMCID: PMC11680602.
- 9: Zara P, Solla P, Damato V, Sechi E. Teaching Video Neurolmage: The "Chameleon Eyes Sign" in Myasthenia Gravis. *Neurology*. 2024 Sep 10;103(5):e209756. doi: 10.1212/WNL.0000000000209756. Epub 2024 Aug 6. PMID: 39106424.
- 10: Orrù V, Serra V, Marongiu M, Lai S, Lodde V, Zoledziewska M, Steri M, Loizedda A, Lobina M, Piras MG, Virdis F, Delogu G, Marini MG, Mingoia M, Floris M, Masala M, Castelli MP, Mostallino R, Frau J, Loreface L, Farina G, Fronza M, Carmagnini D, Carta E, Pilotto S, Chessa P, Devoto M, Castiglia P, Solla P, Zarbo RI, Idda ML, Pitzalis M, Cocco E, Fiorillo E, Cucca F. Implications of disease-modifying therapies for multiple sclerosis on immune cells and response to COVID-19 vaccination. *Front Immunol*. 2024 Jul 15;15:1416464. doi: 10.3389/fimmu.2024.1416464. PMID: 39076966; PMCID: PMC11284103.
- 11: Masala C, Loy F, Pinna I, Manis NA, Ercoli T, Solla P. Olfactory Function as a Potential Predictor of Cognitive Impairment in Men and Women. *Biology (Basel)*. 2024 Jul 5;13(7):503. doi: 10.3390/biology13070503. PMID: 39056696; PMCID: PMC11274230.
- 12: Ashraf H, Dikarlo P, Masia A, Zarbo IR, Solla P, Ijaz UZ, Sechi LA. Network analysis of gut microbial communities reveal key genera for a multiple sclerosis cohort with *Mycobacterium avium* subspecies paratuberculosis infection. *Gut Pathog*. 2024 Jul 10;16(1):37. doi: 10.1186/s13099-024-00627-7. PMID: 38987816; PMCID: PMC11238521.
- 13: Vega-Benedetti AF, Porcedda C, Ercoli T, Fusco G, Burgaletto C, Pillai R, Palmas F, Cantone AF, Angius F, Solla P, De Simone A, Cantarella G, Giallongo C, Sogos V, Defazio G, Carta AR. Immune responses to oligomeric α -synuclein in Parkinson's disease peripheral blood mononuclear cells. *J Neurol*. 2024 Sep;271(9):5916-5929. doi: 10.1007/s00415-024-12554-3. Epub 2024 Jul 10. PMID: 38985290; PMCID: PMC11377674.
- 14: Lu C, Cai X, Zhi S, Wen X, Shen J, Ercoli T, Simula ER, Masala C, Sechi LA, Solla P. Exploring the Association between Cathepsin B and Parkinson's Disease. *Brain Sci*. 2024 May 10;14(5):482. doi: 10.3390/brainsci14050482. PMID: 38790460; PMCID: PMC1119263.
- 15: Ercoli T, Loy F, Masala C, Solla P. Neurological and Psychiatric Disorders in the COVID-19 Era. *Brain Sci*. 2024 Apr 2;14(4):355. doi: 10.3390/brainsci14040355. PMID: 38672007; PMCID: PMC11048350.
- 16: Pilotto S, Floris M, Solla P, Pugliatti M, Zarbo IR. Determinants of self-perceived quality of life in mildly disabled multiple sclerosis patients: a cross-sectional study. *J Neurol*. 2024 Jun;271(6):3455-3461. doi: 10.1007/s00415-024-12244-0. Epub 2024 Mar 25. PMID: 38526763.
- 17: Sechi E, Puci M, Pateri MI, Zara P, Othmani S, Sotgiu S, Saddi MV, Leoni S, Fenu G, Melis M, Sotgiu G, Solla P, Cocco E, Frau J. Epidemiology of aquaporin-4-IgG-positive NMOSD in Sardinia. *Mult Scler Relat Disord*. 2024 May;85:105522. doi: 10.1016/j.msard.2024.105522. Epub 2024 Feb 28. PMID: 38461730.
- 18: Sechi E, Deiana GA, Puci M, Zara P, Ortu E, Porcu C, Carboni N, Chessa P, Ruii E, Nieddu A, Tacconi P, Russo A, Manca D, Sechi MM, Guida M, Ricciardi R, Ercoli T, Mascia MM, Muroi A, Profice P, Saddi V, Melis M,

- Cocco E, Spagni G, Iorio R, Damato V, Maestri M, Sotgiu S, Sotgiu G, Solla P. Epidemiology of seropositive myasthenia gravis in Sardinia: A population-based study in the district of Sassari. *Muscle Nerve*. 2024 May;69(5):637-642. doi: 10.1002/mus.28077. Epub 2024 Mar 8. PMID: 38456240.
- 19: Vaira LA, Tirelli G, Rizzo D, Uderzo F, Avanzini F, Tralbalzini F, Rivelli N, Burger D, Calabrese L, Solla P, Bussu F, Mayo-Yáñez M, Lechien JR, De Riu G, Boscolo-Rizzo P. Validity and reliability of the Questionnaire of Olfactory Disorders for Italian-speaking patients with olfactory dysfunction. *Acta Otorhinolaryngol Ital*. 2024 Feb;44(1):42-51. doi: 10.14639/0392-100X-N2736. PMID: 38420720; PMCID: PMC10914352.
- 20: Gusinu G, Frau C, Trunfio GA, Solla P, Sechi LA. Segmentation of Substantia Nigra in Brain Parenchyma Sonographic Images Using Deep Learning. *J Imaging*. 2023 Dec 19;10(1):0. doi: 10.3390/jimaging10010001. PMID: 38276318; PMCID: PMC11154334.
- 21: Ercoli T, Bagella CF, Frau C, Ruiu E, Othmani S, Gusinu G, Masala C, Sechi LA, Solla P, Defazio G. Phantosmia in Parkinson's Disease: A Systematic Review of the Phenomenology of Olfactory Hallucinations. *Neurol Int*. 2023 Dec 22;16(1):20-32. doi: 10.3390/neurolint16010002. PMID: 38251050; PMCID: PMC10801480.
- 22: Simula ER, Zarbo IR, Arru G, Sechi E, Meloni R, Deiana GA, Solla P, Sechi LA. Antibody Response to HERV-K and HERV-W Envelope Epitopes in Patients with Myasthenia Gravis. *Int J Mol Sci*. 2023 Dec 28;25(1):446. doi: 10.3390/ijms25010446. PMID: 38203616; PMCID: PMC10778599.
- 23: Ercoli T, Solla P, Stone J, Defazio G. Functional neurological disorders and Parkinson's disease - A new research agenda? *Parkinsonism Relat Disord*. 2024 Jan;118:105904. doi: 10.1016/j.parkreldis.2023.105904. Epub 2023 Oct 31. PMID: 37925240.
- 24: Yue Y, Cai X, Lu C, Sechi LA, Solla P, Li S. Unraveling the prognostic significance and molecular characteristics of tumor-infiltrating B lymphocytes in clear cell renal cell carcinoma through a comprehensive bioinformatics analysis. *Front Immunol*. 2023 Oct 16;14:1238312. doi: 10.3389/fimmu.2023.1238312. PMID: 37908350; PMCID: PMC10613680.
- 25: Ercoli T, Barbato F, Bombaci A, Cuffaro L, Di Lorenzo F, Iodice F, Romoli M, Solla P, Defazio G. Neurological Consequences of COVID-19: A Systematic Review of the Pandemic's Impact on Neurology Training. *Brain Sci*. 2023 Aug 10;13(8):1188. doi: 10.3390/brainsci13081188. PMID: 37626544; PMCID: PMC10452502.
- 26: Contini C, Fadda L, Lai G, Masala C, Olanas A, Castagnola M, Messina I, Iavarone F, Bizzarro A, Masullo C, Solla P, Defazio G, Manconi B, Diaz G, Cabras T. A top-down proteomic approach reveals a salivary protein profile able to classify Parkinson's disease with respect to Alzheimer's disease patients and to healthy controls. *Proteomics*. 2024 Feb;24(3-4):e2300202. doi: 10.1002/pmic.202300202. Epub 2023 Aug 4. PMID: 37541286.
- 27: Pinna F, Corda D, Fois C, Maccabeo A, Sechi GP, Solla P. Seizure response to carbamazepine in a patient with CACNA1A-associated epilepsy: A case report. *Seizure*. 2023 Oct;111:68-70. doi: 10.1016/j.seizure.2023.07.017. Epub 2023 Jul 23. PMID: 37540992.
- 28: Zara P, Dinoto A, Carta S, Floris V, Turilli D, Budhram A, Ferrari S, Milia S, Solla P, Mariotto S, Flanagan EP, Lopez Chiriboga AS, Sechi E. Non-demyelinating disorders mimicking and misdiagnosed as NMOSD: a literature review. *Eur J Neurol*. 2023 Oct;30(10):3367-3376. doi: 10.1111/ene.15983. Epub 2023 Jul 19. PMID: 37433584; PMCID: PMC10530555.
- 29: Solla P, Wang Q, Frau C, Floris V, Loy F, Sechi LA, Masala C. Olfactory Impairment Is the Main Predictor of Higher Scores at REM Sleep Behavior Disorder (RBD) Screening Questionnaire in Parkinson's Disease Patients. *Brain Sci*. 2023 Mar 31;13(4):599. doi: 10.3390/brainsci13040599. PMID: 37190564; PMCID: PMC10137056.
- 30: Solla P, Wang Q, Masala C. Role of rapid eye movement sleep behavior disorder (RBD) and other clinical factors in the prediction of cognitive impairment in Parkinson's disease. *Parkinsonism Relat Disord*. 2023 Sep;114:105415. doi: 10.1016/j.parkreldis.2023.105415. Epub 2023 Apr 29. PMID: 37142470.
- 31: Masala C, Solla P, Loy F. Gender-Related Differences in the Correlation between Odor Threshold, Discrimination, Identification, and Cognitive Reserve Index in Healthy Subjects. *Biology (Basel)*. 2023 Apr 12;12(4):586. doi: 10.3390/biology12040586. PMID: 37106786; PMCID: PMC10136322.
- 32: Dinoto A, Zara P, Mariotto S, Ferrari S, Flanagan EP, Budhram A, Orellana D, Turilli D, Solla P, Day GS, Sechi E, Lopez-Chiriboga AS. Autoimmune encephalitis misdiagnosis and mimics. *J Neuroimmunol*. 2023 May 15;378:578071. doi: 10.1016/j.jneuroim.2023.578071. Epub 2023 Mar 16. PMID: 36989703.
- 33: Sechi E, Defazio G, Erre GL, Solla P. Author Response: Teaching Video NeuroImage: Bilateral Hemifacial Spasm in Giant Cell Arteritis. *Neurology*. 2023 Feb 7;100(6):311-312. doi: 10.1212/WNL.0000000000206851. PMID: 36746642; PMCID: PMC9946178.
- 34: Solla P, Masala C, Ercoli T, Frau C, Bagella C, Pinna I, Loy F, Defazio G. Olfactory Impairment Correlates with Executive Functions Disorders and Other Specific Cognitive Dysfunctions in Parkinson's Disease. *Biology (Basel)*. 2023 Jan 10;12(1):112. doi: 10.3390/biology12010112. PMID: 36671804; PMCID: PMC9855400.
- 35: Fadda G, Flanagan EP, Cacciaguerra L, Jitrapaikulsan J, Solla P, Zara P, Sechi E. Myelitis features and outcomes in CNS demyelinating disorders: Comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD. *Front Neurol*. 2022 Nov 7;13:1011579. doi: 10.3389/fneur.2022.1011579. PMID: 36419536; PMCID: PMC9676369.
- 36: Frau C, Masala C, Solla P, Ercoli T, Defazio G. Association between olfactory dysfunction and motor subtypes in Parkinson's disease: are non-tremor-dominant subtypes really uncorrelated to olfactory impairment? *Neurol Sci*. 2023 Feb;44(2):729-730. doi: 10.1007/s10072-022-06445-6. Epub 2022 Oct 11. PMID: 36221040.
- 37: Ashraf H, Solla P, Sechi LA. Current Advancement of Immunomodulatory Drugs as Potential Pharmacotherapies for Autoimmunity Based Neurological Diseases. *Pharmaceuticals (Basel)*. 2022 Aug 29;15(9):1077. doi: 10.3390/ph15091077. PMID: 36145298; PMCID: PMC9504155.
- 38: Idda ML, Pitzalis M, Lodde V, Loizedda A, Frau J, Lobina M, Zoledziwska M, Virdis F, Delogu G, Marini MG, Mingoia M, Masala M, Lorefice L, Fronza M, Carmagnini D, Carta E, Pilotto S, Castiglia P, Chessa P, Uzzau S, Farina G, Solla P, Steri M, Devoto M, Fiorillo E, Floris M, Zarbo RI, Cocco E, Cucca F. Cross-sectional analysis of the humoral response after SARS-CoV-2 vaccination in Sardinian multiple sclerosis patients, a follow-up study. *Front Immunol*. 2022 Aug 18;13:946356. doi: 10.3389/fimmu.2022.946356. PMID: 36059537; PMCID: PMC9433902.
- 39: Solla P, Masala C, Pinna I, Frau C, Ercoli T, Defazio G. Olfactory hallucinations in Parkinson's disease patients and the role of their evaluation in clinical practice. *Parkinsonism Relat Disord*. 2022 Sep;102:141. doi: 10.1016/j.parkreldis.2022.07.020. Epub 2022 Aug 5. PMID: 35948466.
- 40: Sechi E, Gallus E, Solla P, Puggioni D, Amadu AM, Ortu R, Piras M, Defazio G, Erre GL. Teaching Video NeuroImage: Bilateral Hemifacial Spasm in Giant Cell Arteritis. *Neurology*. 2022 Aug 9;99(6):256-257. doi: 10.1212/WNL.0000000000200837. Epub 2022 Jun 3. PMID: 35940893.

- 41: Ercoli T, Masala C, Cadeddu G, Mascia MM, Orofino G, Gigante AF, Solla P, Defazio G, Rocchi L. Does Olfactory Dysfunction Correlate with Disease Progression in Parkinson's Disease? A Systematic Review of the Current Literature. *Brain Sci.* 2022 Apr 19;12(5):513. doi: 10.3390/brainsci12050513. PMID: 35624900; PMCID: PMC9139278.
- 42: Belvisi D, Pellicciari R, Fabbrini A, Costanzo M, Ressa G, Pietracupa S, De Lucia M, Modugno N, Magrinelli F, Dallochio C, Ercoli T, Nicoletti A, Zappia M, Solla P, Bologna M, Fabbrini G, Tinazzi M, Conte A, Berardelli A, Defazio G. Relationship between risk and protective factors and clinical features of Parkinson's disease. *Parkinsonism Relat Disord.* 2022 May;98:80-85. doi: 10.1016/j.parkreldis.2022.04.017. Epub 2022 Apr 29. PMID: 35526494.
- 43: Rosa A, Solla P, Pinna I, Loy F, Masala C. Perception of Sour Taste in Subjects with Olfactory Deficits: Role of Myrtle Aromatization. *Nutrients.* 2024 Dec 30;17(1):105. doi: 10.3390/nu17010105. PMID: 39796539; PMCID: PMC11722836.
- 44: Dinoto A, Sechi E, Flanagan EP, Ferrari S, Solla P, Mariotto S, Chen JJ. Serum and Cerebrospinal Fluid Biomarkers in Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Associated Disease. *Front Neurol.* 2022 Mar 23;13:866824. doi: 10.3389/fneur.2022.866824. PMID: 35401423; PMCID: PMC8983882.
- 45: Dinoto A, Sechi E, Ferrari S, Gajofatto A, Orlandi R, Solla P, Maccabeo A, Maniscalco GT, Andreone V, Sartori A, Manganotti P, Rasia S, Capra R, Mancinelli CR, Mariotto S. Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD. *Mult Scler Relat Disord.* 2022 Feb;58:103424. doi: 10.1016/j.msard.2021.103424. Epub 2021 Nov 22. PMID: 35216793; PMCID: PMC8607690.
- 46: Solla P, Ercoli T, Masala C, Orofino G, Fadda L, Corda DG, Zarbo IR, Meloni M, Sechi E, Bagella CF, Defazio G. Rasagiline Withdrawal Syndrome in Parkinson's Disease. *Brain Sci.* 2022 Feb 5;12(2):219. doi: 10.3390/brainsci12020219. PMID: 35203982; PMCID: PMC8870166.
- 47: Solla P, Masala C, Ercoli T, Orofino G, Loy F, Pinna I, Fadda L, Defazio G. Olfactory Impairment in Parkinson's Disease Patients with Tremor Dominant Subtype Compared to Those with Akinetic Rigid Dominant Subtype: A Pilot Study. *Brain Sci.* 2022 Jan 31;12(2):196. doi: 10.3390/brainsci12020196. PMID: 35203959; PMCID: PMC8869930.
- 48: Bagella CF, Corda DG, Zara P, Elia AE, Ruiu E, Sechi E, Solla P. Chronic Inflammatory Demyelinating Polyneuropathy after ChAdOx1 nCoV-19 Vaccination. *Vaccines (Basel).* 2021 Dec 19;9(12):1502. doi: 10.3390/vaccines9121502. PMID: 34960248; PMCID: PMC8706382.
- 49: Pitzalis M, Idda ML, Lodde V, Loizedda A, Lobina M, Zoledziewska M, Virdis F, Delogu G, Pirinu F, Marini MG, Mingoia M, Frau J, Lorefice L, Fronza M, Carmagnini D, Carta E, Orrù V, Uzzau S, Solla P, Loi F, Devoto M, Steri M, Fiorillo E, Floris M, Zarbo IR, Cocco E, Cucca F. Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients. *Front Immunol.* 2021 Dec 9;12:781843. doi: 10.3389/fimmu.2021.781843. PMID: 34956211; PMCID: PMC8697018.
- 50: Bachetti T, Zanni ED, Adamo A, Rosamilia F, Sechi MM, Solla P, Bozzo M, Ceccherini I, Sechi G. Beneficial Effect of Phenytoin and Carbamazepine on <i>GFAP</i> Gene Expression and Mutant GFAP Folding in a Cellular Model of Alexander's Disease. *Front Pharmacol.* 2021 Dec 7;12:723218. doi: 10.3389/fphar.2021.723218. PMID: 34950024; PMCID: PMC8688807.
- 51: Simula ER, Arru G, Zarbo IR, Solla P, Sechi LA. TDP-43 and HERV-K Envelope-Specific Immunogenic Epitopes Are Recognized in ALS Patients. *Viruses.* 2021 Nov 18;13(11):2301. doi: 10.3390/v13112301. PMID: 34835107; PMCID: PMC8623164.
- 52: Zara P, Floris V, Flanagan EP, Lopez-Chiriboga AS, Weinshenker BG, Solla P, Sechi E. Clinical Significance of Myelin Oligodendrocyte Glycoprotein Autoantibodies in Patients with Typical MS Lesions on MRI. *Mult Scler J Exp Transl Clin.* 2021 Nov 19;7(4):20552173211048761. doi: 10.1177/20552173211048761. PMID: 34820135; PMCID: PMC8606934.
- 53: Redenbaugh V, Flanagan EP, Floris V, Zara P, Bhatti MT, Sanchez F, Koster M, Mariotto S, Pittcock SJ, Chen JJ, Cauli A, Solla P, Sechi E. Exposure to TNF inhibitors is rare at MOGAD presentation. *J Neurol Sci.* 2022 Jan 15;432:120044. doi: 10.1016/j.jns.2021.120044. Epub 2021 Oct 27. PMID: 34728073.
- 54: Ercoli T, Masala C, Pinna I, Orofino G, Solla P, Rocchi L, Defazio G. Qualitative smell/taste disorders as sequelae of acute COVID-19. *Neurol Sci.* 2021 Dec;42(12):4921-4926. doi: 10.1007/s10072-021-05611-6. Epub 2021 Sep 23. PMID: 34557966; PMCID: PMC8459812.
- 55: Arru G, Galleri G, Deiana GA, Zarbo IR, Sechi E, Bo M, Cadoni MPL, Corda DG, Frau C, Simula ER, Manca MA, Galistu F, Solla P, Manetti R, Sechi GP, Sechi LA. HERV-K Modulates the Immune Response in ALS Patients. *Microorganisms.* 2021 Aug 23;9(8):1784. doi: 10.3390/microorganisms9081784. PMID: 34442863; PMCID: PMC8399181.
- 56: Sechi E, Zarbo R, Biancu MA, Chessa P, Idda ML, Orrù V, Lai S, Leoni S, Solla P. Prolonged B-cell depletion after rituximab in AQP4-IgG-positive neuromyelitis optica spectrum disorder. *J Neuroimmunol.* 2021 Sep 15;358:577666. doi: 10.1016/j.jneuroim.2021.577666. Epub 2021 Jul 18. PMID: 34298341.
- 57: Solla P, Masala C, Pinna I, Ercoli T, Loy F, Orofino G, Fadda L, Defazio G. Frequency and Determinants of Olfactory Hallucinations in Parkinson's Disease Patients. *Brain Sci.* 2021 Jun 24;11(7):841. doi: 10.3390/brainsci11070841. PMID: 34202903; PMCID: PMC8301996.
- 58: Modugno N, Antonini A, Tessitore A, Marano P, Pontieri FE, Tambasco N, Canesi M, Fabbrini G, Sensi M, Quatralo R, Solla P, Defazio G, Melzi G, Gualberti G, Lopiano L. Impact of Supporting People with Advanced Parkinson's Disease on Carer's Quality of Life and Burden. *Neuropsychiatr Dis Treat.* 2020 Dec 2;16:2899-2912. doi: 10.2147/NDT.S256217. Erratum in: *Neuropsychiatr Dis Treat.* 2021 Jan 13;17:67-68. doi: 10.2147/NDT.S300706. PMID: 33293815; PMCID: PMC7719333.
- 59: Belvisi D, Pellicciari R, Fabbrini A, Costanzo M, Pietracupa S, De Lucia M, Modugno N, Magrinelli F, Dallochio C, Ercoli T, Terravecchia C, Nicoletti A, Solla P, Fabbrini G, Tinazzi M, Berardelli A, Defazio G. Risk factors of Parkinson disease: Simultaneous assessment, interactions, and etiologic subtypes. *Neurology.* 2020 Nov 3;95(18):e2500-e2508. doi: 10.1212/WNL.00000000000010813. Epub 2020 Sep 17. PMID: 32943485; PMCID: PMC7682833.
- 60: Masala C, Loy F, Piras R, Liscia A, Fadda L, Moat A, Solla P, Defazio G. Effect of Olfactory and Gustatory Dysfunction and Motor Symptoms on Body Weight in Patients with Parkinson's Disease. *Brain Sci.* 2020 Apr 7;10(4):218. doi: 10.3390/brainsci10040218. PMID: 32272584; PMCID: PMC7226465.
- 61: Antonini A, Abbruzzese G, Berardelli A, Modugno N, Stroppa I, Tamma F, Sensi M, Mancini F, Cossu G, Stefani A, Tambasco N, Tessitore A, Fabbrini G, Pontieri FE, Solla P, Bentivoglio AR, Comi C, Minafra B, Riboldazzi G,

Melchionda D, Martino T, Lopiano L. The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson's disease patients. J Neural Transm (Vienna). 2020 Jun;127(6):881-891. doi: 10.1007/s00702-020-02175-1. Epub 2020 Mar 24. Erratum in: J Neural Transm (Vienna). 2021 Jun;128(6):863-865. doi: 10.1007/s00702-020-02200-3. PMID: 32212015.